Antibody Information
General Information of This Antibody
| Antibody ID | ANI0MRCNB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Iladatuzumab |
|||||
| Organization | Roche Holding AG |
|||||
| Indication | Neoplasms |
|||||
| Synonyms |
MCDS0593A; RO7032005
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | B-cell antigen receptor complex-associated protein beta chain (CD79B) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNY
NEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSSCST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNY
NEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
CSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFSSYW
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
ILPGGGDT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
TRRVPIRLDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLES
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLES
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
QSVDYEGDSF
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
AAS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQSNEDPLT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Iladatuzumab vedotin [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
46.67%
|
|||
| Patients Enrolled |
B-non Hodgkin lymphoma (NHL) that had relapsed after or failed to respond to at least one prior treatment regimen and for which no suitable therapy of curative intent or higher priority existed.
|
||||
| Administration Dosage |
The phase Ia, starting dose of 0.30 mg/kg administered intravenously once every 3 weeks (Q3W; 1 cycle = 21 days); The phase Ib portion evaluated DCDS0780A in dose-escalation cohorts starting at one dose level below that tolerated by completed monotherapy cohorts, and in combination with a fixed dose of rituximab (375 mg/m2); up to approximately 1 year or until disease progression or unacceptable toxicity.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02453087 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open-label, multicenter, phase 1/1b dose escalation study evaluating the pharmacokinetics, safety, tolerability, and preliminary efficacy of DCDS0780A, alone or in combination with rituximab, or obinutuzumab, in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma.
|
||||
| Primary Endpoint |
Response rate in all-treated patients (N=60) was 46.67% (n=28), including 17 complete responses (28.33%) and 11 partial responses (18.33%). The median duration of response (15.20 months) was the same for all responders (n=28) and patients with DLBCL (n=20).
|
||||
| Other Endpoint |
The median PFS for all patients on study (N =60) was 4.40 months [95% CI,2.60-13.20], and 3.90 months (95% CI,2.40-9.50) for patients with DLBCL (n=41); PFS for pooled subgroups are indicated. The median DoR for the 28 responders among all patients was 15.20 months (95% CI,8.40-N.E.).
|
||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.